Microorganisms, 2021 Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács +7 more
doaj +1 more source
Journal of Fungi, 2020 Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth +9 more
doaj +1 more source
Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris [PDF]
, 2019 The enigmatic yeast Candida auris has emerged over the last decade and rapidly penetrated our consciousness. The global threat from this multidrug-resistant yeast has generated a call to arms from within the medical mycology community.
Kean, Ryan, Ramage, Gordon
core +2 more sources
Development of the Invasive Candidiasis Discharge [I Can Discharge] Model: A Mixed Methods Analysis [PDF]
, 2022 Patients with invasive candidiasis (IC) have complex medical and infectious disease problems that often require continued care after discharge. This study aimed to assess echinocandin use at hospital discharge and develop a transition of care (TOC) model
Almutairi, Masaad Saeed +9 more
core +3 more sources
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus [PDF]
Antimicrobial Agents and Chemotherapy, 2019 We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus .
Nathan P. Wiederhold +6 more
openaire +2 more sources
Rezafungin: an opportunity to personalize the treatment of patients with candidemia. [PDF]
Crit CareHonore PM, Cornely OA, Soriano A.
europepmc +3 more sources
Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting? [PDF]
, 2022 The study of the pharmacological properties of an antifungal agent integrates the drug pharmacokinetics, the fungal growth inhibition, the fungicidal effect and the postantifungal activity, laying the basis to guide optimal dosing regimen selection.
Eraso, Elena +5 more
core +2 more sources
Echinocandins – structure, mechanism of action and use in antifungal therapy
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well.
Mateusz Szymański +4 more
doaj +1 more source
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
Benzylic Dehydroxylation of Echinocandin antifungal drugs restores efficacy against resistance conferred by mutated Glucan Synthase [PDF]
, 2022 Each year, infections caused by fungal pathogens claim the lives of about 1.6 million people and affect the health of over a billion people worldwide.
Carmeli, Shmuel +7 more
core +1 more source